Biomarin Pharmaceutical (BMRN) Asset Writedowns and Impairment (2012 - 2025)
Biomarin Pharmaceutical (BMRN) posted Asset Writedowns and Impairment of $116.2 million for Q4 2025, up 3817.8% on a QoQ basis from $3.0 million in Q1 2025, and up 684.45% year-over-year from $14.8 million in Q4 2024.
Biomarin Pharmaceutical (BMRN) Asset Writedowns and Impairment (2012 - 2025) Analysis & Trends
Biomarin Pharmaceutical's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $116.2 million for Q4 2025.
- Quarterly Asset Writedowns and Impairment rose 684.45% year-over-year to $116.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $116.2 million (up 24623.42% YoY) and the FY2025 annual result came in at $119.2 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $116.2 million for Q4 2025 at Biomarin Pharmaceutical, up from $3.0 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $116.2 million in Q4 2025 and bottomed at -$19.9 million in Q4 2024.
- A 3-year average of $20.3 million and a median of $9.7 million in 2024 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment sank 242.06% — and 2025, when it jumped 684.45%.
- Biomarin Pharmaceutical's Asset Writedowns and Impairment stood at $14.0 million in 2023, then sank by 242.06% to -$19.9 million in 2024, then soared by 684.45% to $116.2 million in 2025.
- Business Quant data shows BMRN's Asset Writedowns and Impairment at $116.2 million in Q4 2025, $3.0 million in Q1 2025, and -$19.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn |
| 10 | Biomarin Pharmaceutical | 11.70 Bn | 9.48 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 116.24 Mn |
| Dec 31, 2025 | 116.24 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -19.89 Mn |
| Dec 31, 2024 | -19.89 Mn |
| Sep 30, 2024 | 6.78 Mn |
| Sep 30, 2024 | 6.78 Mn |
| Jun 30, 2024 | 9.67 Mn |
| Jun 30, 2024 | 9.67 Mn |
| Dec 31, 2023 | 14.00 Mn |
| Dec 31, 2023 | 14.00 Mn |
| Mar 31, 2023 | 12.65 Mn |
| Mar 31, 2023 | 12.65 Mn |
| Dec 31, 2015 | 198.70 Mn |
| Dec 31, 2015 | 198.70 Mn |
| Dec 31, 2014 | -360,000.00 |
| Dec 31, 2014 | -360,000.00 |
| Sep 30, 2014 | 35,000.00 |
| Sep 30, 2014 | 35,000.00 |